Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04862091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Abiraterone Acetate Tablets (I)
DRUG: ZYTIGA®

Sponsor

Jiangsu HengRui Medicine Co., Ltd.